As tau-PET has shown high performance in discriminating AD from non-AD neurodegenerative diseases, it is expected to have added value over current diagnostic processes in patients with residual diagnostic uncertainty after routine diagnostic work-up. The gene discussed is MAPT; the disease is neurodegenerative disease.